Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.
about
Evolving concepts in cancer therapy through targeting sphingolipid metabolismRoles and regulation of neutral sphingomyelinase-2 in cellular and pathological processesFTY720 induces apoptosis of M2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levelsNon-synonymous variations in cancer and their effects on the human proteome: workflow for NGS data biocuration and proteome-wide analysis of TCGA data.Stress-induced sphingolipid signaling: role of type-2 neutral sphingomyelinase in murine cell apoptosis and proliferation.Re-configuration of sphingolipid metabolism by oncogenic transformation.Sphingomyelin metabolism at the plasma membrane: implications for bioactive sphingolipids.Prenatal tobacco smoke exposure is associated with childhood DNA CpG methylation.Identification of novel anionic phospholipid binding domains in neutral sphingomyelinase 2 with selective binding preferenceNeutral sphingomyelinase-2 mediates growth arrest by retinoic acid through modulation of ribosomal S6 kinaseProtein phosphatase 2A and neutral sphingomyelinase 2 regulate IRAK-1 protein ubiquitination and degradation in response to interleukin-1betaAssociation between CLN3 (Neuronal Ceroid Lipofuscinosis, CLN3 Type) Gene Expression and Clinical Characteristics of Breast Cancer PatientsTumor Necrosis Factor-α (TNFα)-induced Ceramide Generation via Ceramide Synthases Regulates Loss of Focal Adhesion Kinase (FAK) and Programmed Cell Death.The hyaluronic acid inhibitor 4-methylumbelliferone is an NSMase2 activator-role of Ceramide in MU anti-tumor activitySphingolipid metabolism cooperates with BAK and BAX to promote the mitochondrial pathway of apoptosisGenome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma.Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapyTargeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials.Mammalian neutral sphingomyelinases: regulation and roles in cell signaling responses.Remodeling of sphingolipids by plasma membrane associated enzymes.Acid sphingomyelinase in macrophage biology.Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.The roles of neutral sphingomyelinases in neurological pathologies.Sphingolipid metabolism and neutral sphingomyelinases.Sphingolipids in the DNA damage response.Genomic and transcriptomic profiling of resistant CEM/ADR-5000 and sensitive CCRF-CEM leukaemia cells for unravelling the full complexity of multi-factorial multidrug resistanceSoluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity.Lipidomic profiling of patient-specific iPSC-derived hepatocyte-like cells.Epigenetic reprogramming in liver fibrosis and cancer.Structure of human nSMase2 reveals an interdomain allosteric activation mechanism for ceramide generation.Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis.Transposon mutagenesis screen in mice identifies TM9SF2 as a novel colorectal cancer oncogeneFlupirtine derivatives as potential treatment for the neuronal ceroid lipofuscinoses
P2860
Q26863646-BB64D1EA-AE4F-4131-802D-E54F9F0AECD2Q27022944-9582D910-9945-41C4-9B09-F3D4D25A8488Q28541065-6D5B424B-CCB4-4B74-A1E7-6A59C90C0BA3Q30742924-EA195CE1-6901-4B39-8C76-938EAE5BC046Q33547469-3F486259-366A-4510-9ED2-33B353BD8E52Q33649823-FA1B8259-E2E2-4E6E-A7D6-F43480E1ADBCQ33798777-0844D8BC-05EB-46C3-902F-565EEA090CDCQ33806521-6C20B43F-047C-47D7-A85D-36AB8EFC7C13Q35063109-DD00DE8C-A99E-4F28-84D9-BF62467D1790Q35065231-CF7FBB0F-3FC6-4474-A51B-E280D44D70FFQ35213446-7FD52241-0E9F-47CE-9A3F-FC7B49510484Q36147348-BF480B20-1C7E-463E-BF2F-C107065FED5DQ36283299-9AFD378D-F778-4DAF-9CE6-4D39D68C3364Q36404904-F96F8568-5E3C-4729-9EB2-A2A09A92F2A3Q36422392-C42584F6-D99E-4D7A-AB12-21D7DA5335F3Q37481324-8CA413B9-83FA-4E1B-8C53-39F819F5530CQ37486242-1337BB46-45BC-496E-AB18-531D37F299D9Q37718254-6BF75E82-907C-4252-B55A-94C303E6F2CDQ37765497-1D1C988C-B9E1-46F8-A8A8-B73D4749F107Q37823410-39BADC09-04C9-4AA5-8FD3-0D8D241E2FD6Q37870853-408E06BB-10F3-4739-A0DE-B9CD34CD31AAQ37880161-1FA554CB-043C-43A2-BB9F-108ED72778D2Q37975165-B893866D-8781-40A9-B83A-9D435C116FF0Q38098404-7F8536CB-C843-47EA-9EC3-C92CCC121683Q38272799-318ACFAE-3CEE-4DD8-A72B-4AEA5CBBAA53Q38797514-36851588-EC93-4F5F-8882-526E93E6EC04Q40372471-DC5AD8C2-70C5-4F18-AD7C-0E0B4257E3F2Q41664781-1C0D59C3-67AF-4D47-BE84-97C949584230Q47157566-273515D9-FCF6-4591-9820-12A46CBF987FQ47844641-D8982A93-2D87-4E22-BB3A-45184FA99018Q51813863-EF6A4582-526C-43DD-AA9F-758D2070B6D1Q58549068-9BBB00AE-C458-4865-8052-C14DF4C928C1Q58779774-770374FD-C809-48EF-BD1F-57EC35075C35
P2860
Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Mutations in the neutral sphin ...... de pathway in human leukemias.
@ast
Mutations in the neutral sphin ...... de pathway in human leukemias.
@en
type
label
Mutations in the neutral sphin ...... de pathway in human leukemias.
@ast
Mutations in the neutral sphin ...... de pathway in human leukemias.
@en
prefLabel
Mutations in the neutral sphin ...... de pathway in human leukemias.
@ast
Mutations in the neutral sphin ...... de pathway in human leukemias.
@en
P2093
P2860
P1433
P1476
Mutations in the neutral sphin ...... de pathway in human leukemias.
@en
P2093
A Thomas Look
Andrea I McClatchey
Daniel A Haber
Daphne W Bell
David T Scadden
Farshid Dayyani
Meagan Goodwin
Olivier A Bernard
Ross A Okimoto
Sara M Haserlat
P2860
P304
P356
10.1182/BLOOD-2007-10-113068
P407
P577
2008-02-25T00:00:00Z